Study of triple therapy for untreated liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of three drugs (zanzalintinib, durvalumab, and tremelimumab) for people with liver cancer that cannot be removed by surgery and who have not received prior systemic treatment. The goal is to see if this combination can shrink or slow the growth of the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer that cannot be removed with surgery.
- You have not had any previous systemic cancer treatment (like chemotherapy or immunotherapy) for your liver cancer.
- Your overall health is good (ECOG performance status 0 or 1).
- You are willing to have a fresh tumor biopsy (or provide a stored tumor sample) before starting the study.
- You do not have serious heart problems, uncontrolled high blood pressure, or a history of bleeding in the recent past.
- You do not have an active autoimmune disease that requires immune-suppressing medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, zanzalintinib and durvalumab, as maintenance therapy for people with advanced liver cancer who have already responded to an initial treatment. The goal is to see if this combination can keep the cancer from growing longer.
This study tests a combination of three treatments—TACE (a procedure that blocks blood flow to the tumor), lenvatinib (a targeted therapy pill), and tislelizumab (an immunotherapy)—for people with liver cancer that has spread into the bile ducts and can't be removed by surgery. The goal is to see if this triple therapy helps shrink or control the cancer.
This trial tests if combining two immunotherapy drugs (atezolizumab and bevacizumab) with a brain-health medicine (memantine) can help people with advanced liver cancer that isn't treatable with surgery. It aims to see if this triple therapy works better than standard options.
This Phase 2 trial tests three medicines together (durvalumab, tremelimumab, and bevacizumab) to treat non-surgical (non-resectable) liver cancer. It may help shrink tumors and slow disease progression by boosting the immune system and blocking tumor blood supply.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
This trial combines three treatments: Y-90 radioembolization (targeted radiation to liver tumors), two immunotherapy drugs (durvalumab and tremelimumab), and a targeted oral drug (zanzalintinib) to see if this combination can shrink or control liver cancer that cannot be removed by surgery or transplant. It may be an option for people whose cancer has not spread beyond the liver and who have not had prior systemic treatment.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.